Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ueli Nachbur

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Nature Microbiology|February 14, 2017
Erratum: EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammationJaclyn S Pearson, Cristina Giogha, Sabrina Mühlen, et al.
Nature|September 13, 2013
A type III effector antagonizes death receptor signalling during bacterial gut infectionJaclyn S Pearson, Cristina Giogha, Sze Ying Ong, et al.
Frontiers in Chemistry|May 2, 2022
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro InhibitorsDale J Calleja, Nathan Kuchel, Bernadine G C Lu, et al.
Nature Communications|March 18, 2015
A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine productionUeli Nachbur, Che A Stafford, Aleksandra Bankovacki, et al.
Gastroenterology|August 29, 2022
Epigenetic Silencing of RIPK3 in Hepatocytes Prevents MLKL-mediated Necroptosis From Contributing to Liver PathologiesSimon P Preston, Michael D Stutz, Cody C Allison, et al.
Nature Communications|April 3, 2025
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVIDStefanie M Bader, Dale J Calleja, Shane M Devine, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Nature Microbiology|February 14, 2017
Erratum: EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammationJaclyn S Pearson, Cristina Giogha, Sabrina Mühlen, et al.
Nature|September 13, 2013
A type III effector antagonizes death receptor signalling during bacterial gut infectionJaclyn S Pearson, Cristina Giogha, Sze Ying Ong, et al.
Frontiers in Chemistry|May 2, 2022
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro InhibitorsDale J Calleja, Nathan Kuchel, Bernadine G C Lu, et al.
Nature Communications|March 18, 2015
A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine productionUeli Nachbur, Che A Stafford, Aleksandra Bankovacki, et al.
Gastroenterology|August 29, 2022
Epigenetic Silencing of RIPK3 in Hepatocytes Prevents MLKL-mediated Necroptosis From Contributing to Liver PathologiesSimon P Preston, Michael D Stutz, Cody C Allison, et al.
Nature Communications|April 3, 2025
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVIDStefanie M Bader, Dale J Calleja, Shane M Devine, et al.
Pageof 4